Neurocrine Biosciences, Inc. (NBIX) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome everyone joining today's Neurocrine Biosciences Reports Q2 2026 earnings call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. To register to ask a question at any time, please press star 1 on your telephone keypad. Please note this call is being recorded. Todd Tushla, Vice President of Investor Relations. Please go ahead. Happy Thursday, everyone. Welcome to Neurocrine Biosciences' second quarter 2026 earnings call. With me today on the call are Kyle Gano, Chief Executive Officer, Matt Abernethy, Chief Financial Officer, Eric Benevich, Chief Commercial Officer, Sanjay Keswani, Chief Medical Officer, and in his well-deserved new role as Chief Business Officer, Samir Sadanti. During today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. In addition, some of the information discussed today includes non-GAAP financial measures that have not been calculated in accordance with U.S. GAAP. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are presented in the tables at the end of our earnings release issued earlier today, which has been posted on the investor relations page of Neurocrine's website. After prepared remarks, we'll jump into Q&A. Now, I'll hand the call off to Kyle. Thanks, Todd. Good afternoon, everyone. Neurocrine's second quarter performance demonstrates the power of a diversified growth strategy built to compound over time. Our commercial portfolio of first-in-class medicines, Ingreza, C...